Aliases & Classifications for Cavernous Malformation

About this section

Aliases & Descriptions for Cavernous Malformation:

Name: Cavernous Malformation 46

Summaries for Cavernous Malformation

About this section
NINDS:46 Cerebral cavernous malformations (CCMs) are vascular lesions comprised of clusters of tightly packed, abnormally thin-walled small blood vessels (capillaries) that displace normal neurological tissue in the brain or spinal cord.

MalaCards based summary: Cavernous Malformation is related to hydrocephalus and cerebral cavernous malformations 3. An important gene associated with Cavernous Malformation is CCM2 (CCM2 Scaffolding Protein). Affiliated tissues include brain, spinal cord and bone, and related mouse phenotypes are tumorigenesis and muscle.

Related Diseases for Cavernous Malformation

About this section

Graphical network of the top 20 diseases related to Cavernous Malformation:



Diseases related to cavernous malformation

Symptoms for Cavernous Malformation

About this section

Drugs & Therapeutics for Cavernous Malformation

About this section

Drugs for Cavernous Malformation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Anticholesteremic AgentsPhase 1, Phase 2, Phase 01732
2Hypolipidemic AgentsPhase 1, Phase 2, Phase 02228
3Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 1, Phase 2, Phase 01804
4AntimetabolitesPhase 1, Phase 2, Phase 09454
5Calcium, DietaryPhase 1, Phase 24678
6Atorvastatin CalciumPhase 1, Phase 2714134523-03-8
7
Doxycyclineapproved, investigationalPhase 1219564-25-054671203, 5281011
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6╬▒-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Adoxa
Alodox
Alti-Doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Doryx
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy 100
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline
Doxycycline (200mg/day) or Placebo
Doxycycline (INN)
 
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline hydrochloride
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
Morgidox
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Ocudox
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Monohydrate
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
8Antiprotozoal AgentsPhase 11730
9Antiparasitic AgentsPhase 11854
10Anti-Bacterial AgentsPhase 19140
11AntimalarialsPhase 11058
12Anti-Infective AgentsPhase 117220
13
SimvastatinapprovedPhase 049379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
14AstragalusNutraceutical48

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile DysfunctionRecruitingNCT01089387Phase 1, Phase 2
2Atorvastatin Therapy in Cerebral Cavernous Malformation: A Proof of Concept Phase I/II TrialNot yet recruitingNCT02603328Phase 1, Phase 2
3Influence of MMP on Brain AVM HemorrhageCompletedNCT00783523Phase 1
4Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of StatinsCompletedNCT01764451Phase 0
5Modifiers of Disease Severity in Cerebral Cavernous MalformationsRecruitingNCT01764529
6Genetic Disease Gene IdentificationEnrolling by invitationNCT00916903

Search NIH Clinical Center for Cavernous Malformation

Genetic Tests for Cavernous Malformation

About this section

Anatomical Context for Cavernous Malformation

About this section

MalaCards organs/tissues related to Cavernous Malformation:

33
Brain, Spinal cord, Bone, Bone marrow, Endothelial, T cells, Heart

Animal Models for Cavernous Malformation or affiliated genes

About this section

MGI Mouse Phenotypes related to Cavernous Malformation:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.9CCM2L, KRIT1, PDCD10, PTEN
2MP:00053698.5CCM2, CCM2L, KRIT1, PDCD10, PTEN
3MP:00028738.4CCM2, CCM2L, ITGB1BP1, PDCD10, PTEN
4MP:00053918.3CCM2, ITGB1BP1, KRIT1, PDCD10, PTEN

Publications for Cavernous Malformation

About this section

Articles related to Cavernous Malformation:

(show top 50)    (show all 380)
idTitleAuthorsYear
1
Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. (25797915)
2015
2
Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma. (24294352)
2013
3
Asymptomatic urethritis is common and is associated with characteristics that suggest sexually transmitted etiology. (23407472)
2013
4
Direct tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis. (22412233)
2012
5
Effects of IGF-binding protein 5 in dysregulating the shape of human hair. (20944648)
2011
6
Diagnostic approach to ocular toxoplasmosis. (21770803)
2011
7
Structure of the membrane-tethering GRASP domain reveals a unique PDZ ligand interaction that mediates Golgi biogenesis. (21515684)
2011
8
Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies. (20551689)
2010
9
Giant cell tumor of the thoracic spine: case report and review of the literature. (18207522)
2009
10
Clavicular nonunion associated with thoracic outlet syndrome treated with Knowles pin fixation, autogenous bone marrow graft, and autologous fibrin clots. (19088549)
2009
11
Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. (19145645)
2009
12
Fatal Addison's disease in a teenager. (19474361)
2009
13
Reactive arthritis. (19341180)
2009
14
The preservation of insulin sensitivity in obese women without diabetes. (18672628)
2008
15
Characterization of autonomic dysfunction in patients with irritable bowel syndrome using fingertip blood flow. (18248583)
2008
16
The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. (18348986)
2008
17
The construction and identification of the PRNP vectors with ubiquitin or the lysosome-targeting signal]. (19544632)
2008
18
BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. (17276340)
2007
19
Cables links Robo-bound Abl kinase to N-cadherin-bound beta-catenin to mediate Slit-induced modulation of adhesion and transcription. (17618275)
2007
20
Modified Echocardiographic views for concordant atrio-ventricular connection with discordant ventriculo-arterial connection or double outlet right ventricle and sub-pulmonary ventricular septal defect. (22368672)
2007
21
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. (16507114)
2006
22
The role of vestibular rehabilitation in the treatment of Meniere's disease. (16143175)
2005
23
Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. (15364550)
2004
24
Mitosis: MCAK under the aura of Aurora B. (15120087)
2004
25
Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. (15178583)
2004
26
Over-expression of Mn-superoxide dismutase as a marker of oxidative stress in lesional skin of chronic idiopathic urticaria. (12780723)
2003
27
Protein kinase CK2 phosphorylates and interacts with deoxyhypusine synthase in HeLa cells. (14749535)
2003
28
The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. (12855749)
2003
29
Structure-activity relationship for human cytochrome P450 substrates and inhibitors. (11996013)
2002
30
The NF-kappaB pathway in human endometrium and first trimester decidua. (11160844)
2001
31
Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells. (10903736)
2000
32
Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. (10468529)
1999
33
Bone marrow transplantation in a Hunter patient with P266H mutation. (10493987)
1999
34
S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. (10493528)
1999
35
Histone- and protamine-DNA association: conservation of different patterns within the beta-globin domain in human sperm. (9584175)
1998
36
Trimethoprim-sulfamethoxazole-induced renal tubular acidosis in a patient with AIDS. (7620045)
1995
37
Basic aspects of GABA-transaminase in neuropsychiatric disorders. (7628073)
1995
38
Significance of the serum CA125 level in recurrent ovarian cancer. (1320853)
1992
39
Preventing neonatal herpes--current strategies. (1311801)
1992
40
Frequency of the phenylalanine deletion (delta F508) in the CF gene of Belgian cystic fibrosis patients. (1673094)
1991
41
Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. (1724021)
1991
42
Purified first and third trimester placental trophoblasts differ in in vitro hormone secretion. (2318939)
1990
43
Identification and chromosomal mapping of new human tyrosine kinase genes. (2156206)
1990
44
Bardet-Biedl syndrome and related disorders. (7065946)
1982
45
Acute mountain sickness. (64667)
1977
46
Demonstration of a little known cause of infantile epilepsy, occipital porencephaly, by computerized tomography (CT). (401048)
1977
47
Arsine induced anuria. (13936466)
1963
48
Roentgenologic features of fracture of the tibial tuberosity (Osgood-Schlatter's disease). (13478504)
1957
49
50

Variations for Cavernous Malformation

About this section

Expression for genes affiliated with Cavernous Malformation

About this section
Search GEO for disease gene expression data for Cavernous Malformation.

Pathways for genes affiliated with Cavernous Malformation

About this section

GO Terms for genes affiliated with Cavernous Malformation

About this section

Biological processes related to Cavernous Malformation according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of focal adhesion assemblyGO:00518959.9ITGB1BP1, PTEN
2negative regulation of protein bindingGO:00320919.9CCM2L, ITGB1BP1
3negative regulation of ERK1 and ERK2 cascadeGO:00703739.5ITGB1BP1, PTEN
4protein stabilizationGO:00508219.1CCT7, PDCD10, PTEN
5positive regulation of cell proliferationGO:00082848.8ITGB1BP1, PDCD10, PTEN

Sources for Cavernous Malformation

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet